Skip to main content

BIOLyte Oral Rehydration Solution with prebiotic and zinc (Orange flavour) (Neptune Bio-Innovations Pty Ltd)

Product Name
BIOLyte Oral Rehydration Solution with prebiotic and zinc (Orange flavour)
ARTG
280390
Date of review outcome
Date of publication
Dec-20
Outcome
Medicine continues to be permitted for supply. Batches released from December 2020 must carry a corrected label with a declaration for the presence of sugars and advertising for gastroenteritis removed.
Is it safe to continue using this medicine?
Yes, if you follow the recommended actions below
What action should consumers take?
Seek advice from a suitably qualified health professional if you are or have been taking this medicine to relieve symptoms of gastroenteritis. Consider whether this medicine is right for you based on it potentially not working as expected in relation to boosting immunity. Take note that this medicine contains sugars.
Review scope
Random
Information reviewed
ARTG Record, Labels, Website
Issues related to safety
The label for the medicine did not appropriately declare the presence of ‘sugars’. Ingredient and substance declarations for listed medicines, including the way they are described on a label, are in place to ensure safe use by consumers who may be affected by their presence. However, this is unlikely to pose an immediate risk to consumer health and safety as the label contained references to both the presence of sucrose and glucose contained in the medicine. Additionally, the label and website of the medicine advertised its use for gastroenteritis which is a serious condition requiring diagnosis, treatment or supervision by a suitably qualified health professional. This is not permitted for medicines that are available for self-selection without prior evaluation by the TGA. The references to gastroenteritis have the potential to lead consumers with this condition to delay access to timely medical advice or treatment when required, resulting in adverse outcomes. However, the label also warns consumers to seek medical advice if symptoms persist. As such, the medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
The website claimed that the medicine may ‘boost immunity’. However, this claim was not covered by the sponsor’s certification that they held evidence to substantiate it.
Actions taken during the review
The TGA required the sponsor to correct the issues with the medicine. The sponsor updated the label and website to remove the advertising of the medicine for gastroenteritis and include the sugar declaration on the label.

Help us improve the Therapeutic Goods Administration site